ReviewCancer management and research2018
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Nathan M Denlinger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papertrialcites it